Status:
COMPLETED
Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.
Lead Sponsor:
Novartis
Conditions:
Chronic Constipation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists. The aim of this study was to evaluate the efficacy and safet...
Eligibility Criteria
Inclusion
- A 6-month history of constipation defined as \<3 complete spontaneous bowel movements per week and \>1 of the following symptoms \>25% of the time: hard stools, sensation of incomplete evacuation and straining
Exclusion
- Patients with cancer, inflammatory bowel disease or other structural bowel disease
- Past or current diagnosis of irritable bowel syndrome were excluded.
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
1026 Patients enrolled
Trial Details
Trial ID
NCT00141089
Start Date
March 1 2004
End Date
February 1 2005
Last Update
February 1 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.